Joshua Urban, MD
Orthopaedic Surgery · Omaha, NENPI 1942260880
Payments from drug & device makers
Across 504 payments — averaging $2199.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$652K
- Pacira Pharmaceuticals Incorporated$420K
- Myoscience Inc.$18K
- Pacira Cryotech Incorporated$13K
- Johnson & Johnson$5K
- Medical Device Business Services, Inc.$411
- plus $636 from 5 others
What the payments were for
- Consulting fees$371,84278%
- Speaking & faculty fees$54,13211%
- Travel & lodging$38,2968%
- Food & beverage$10,6332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 14 | $652,255 |
| Pacira Pharmaceuticals Incorporated | 392 | $419,619 |
| Myoscience Inc. | 26 | $18,047 |
| Pacira Cryotech Incorporated | 13 | $12,539 |
| Johnson & Johnson(2 entities) | 46 | $4,850 |
| Medical Device Business Services, Inc. | 5 | $411 |
| Orthogrid Systems Inc | 2 | $210 |
| Sanara Medtech Inc. | 1 | $182 |
| Smith+Nephew | 2 | $177 |
| Abiomed | 2 | $37 |
| Solventum Corporation | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iovera$207,805
- IOVERA SYSTEM$133,619
- EXPAREL$126,810
- Zilretta$37,798
- ACTIS$2,091
- Velys$1,600
- ATTUNE$345
- Kincise Surgical Automated System$226
- CellerateRx$182
- CORI$134
- HIP7$134
- Megadyne$111
How this compares
$1,108,357 in reported general payments places this provider in the 95th percentile of 155 orthopaedic surgery providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 119 | $212 |
| Amoxicillin | 221 | $211 |
| Cephalexin | 48 | $199 |
| Clindamycin Hcl | 31 | $42 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Omaha
- Edward FehringerOmaha$2M
- Sayfe JassimOmaha$460K
- Beau KildowOmaha$353K
- Matthew DilisioOmaha$58K
- Samuel DubrowOmaha$34K
- Jonathan BuzzellOmaha$33K
- Michael StojanovicOmaha$22K
- Kirk HuttonOmaha$15K
- Sean McGarryOmaha$12K
- Clayton ThorOmaha$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.